# MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

> **NCT03004105** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma
- Advanced Lung Cancer
- Recurrent Nonsmall Cell Lung Cancer

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Durvalumab
- **BEHAVIORAL:** Phone Calls

## Key facts

- **NCT ID:** NCT03004105
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-05
- **Primary completion:** 2023-05
- **Final completion:** 2024-05
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate funding
- **Last updated:** 2018-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004105, "MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03004105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*